Tempus AI presents data on AI pre-screening panel for lung cancer
The panel achieved greater than 80% sensitivity across all 12 biomarkers assessed, with sensitivity exceeding 90% for several.
GetSignal Tempus AI Inc TEM
On October 19, 2026, Tempus AI presented results from a study of an AI-enabled pre-screening panel for patients with advanced non-small cell lung cancer (NSCLC).
Tempus AI said the data support the panel's potential to identify patients for confirmatory biomarker testing.
Key facts
- Sensitivity across biomarkers
- Greater than 80% across all 12 biomarkers assessed
- Higher sensitivity
- Exceeding 90% for several biomarkers
- Patient population
- Advanced non-small cell lung cancer (NSCLC)
Source: The company's release on Business Wire, October 19, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
